SunWay Biotech, a subsidiary of Bora Pharmaceuticals Group, announced on the 19th that its board of directors has approved a strategic investment in Wonders Company Ltd. With a cash injection of NT$650 million, SunWay will acquire a 30% stake in the company, along with one board seat. The transaction is expected to close in September.
Wonders Company has successfully launched multiple best-selling Weider health supplement products in the past. This partnership is expected to create strong synergies by combining SunWay’s R&D expertise and production capacity with Bora Group’s international experience, helping expand market share for dietary supplements in Taiwan while diversifying SunWay’s reliance on agency and re-licensing models, ultimately delivering mutual benefits for shareholders.
At the signing ceremony on the 19th, Wonders Chairperson Hsu-Wen Chen, Bora Pharmaceuticals Chairman Bobby Sheng, and SunWay Biotech General Manager Pan, Chia-Yueh were in attendance.
Bobby Sheng commented: “In the health supplement market, distribution channels and brand value are the most valuable assets, requiring substantial time and capital to build. Both Wonders and SunWay bring unique long-term market advantages. Through this collaboration, we look forward to opening new pathways for U.S.-style brand operations with SunWay’s products. Weider’s flagship instant soluble probiotic blends have long been popular among Taiwanese consumers, consistently achieving sales of tens of millions of packs per month. By combining SunWay’s R&D strength with Bora’s extensive pharmacy distribution network, we aim to deliver a wider range of products tailored to market needs and boost revenue. With SunWay’s new Xizhi plant nearing completion, cost advantages from in-house production will further strengthen our competitiveness.”
Hsu-Wen Chen emphasized that this transaction represents a pivotal move driven by both companies’ leadership teams based on long-term industry trends and growth strategies. She said: “Going forward, while maintaining operational independence, both sides will engage in deeper technical collaboration and channel integration to maximize synergies across product development, R&D, and marketing. With decades of focus on probiotics, Wonders has established a solid market share and robust R&D capabilities, securing its leading position in Taiwan. Through this alliance, both companies will integrate core technologies and product strengths, strengthen supply chain collaboration, and deliver a broader portfolio of scientifically backed, high-potential health supplement products.”
Looking ahead, SunWay is positioning itself as a health supplement specialist. Beyond its raw material product lines, it will actively leverage its clinically validated brand Dr. Bora to expand into different consumer segments and distribution channels. This dual-track model of multi-brand collaboration and vertical integration is seen as a key competitive advantage.
SunWay’s raw material R&D capabilities have long been recognized by its partners, making it a trusted supplier for Taiwan’s best-selling red yeast rice health products. Backed by Bora Pharmaceuticals’ strong pharmaceutical background, the company enjoys a first-mover advantage in innovative formulations and product positioning. With stable demand from European clients and ongoing collaboration to co-develop new products, the completion of the Xizhi plant marks an acceleration of its efforts to expand market share in health supplements—building an end-to-end business model that spans functional ingredient R&D, dosage form design, clinical validation, and branded operations, shaping the next generation of large-scale health supplement enterprises.
Resource: 保瑞集團晨暉生技6.5億元入股望德斯國際 取得30%股份及一席董事
